X

Rubriques :

Maroc - STOCKHEAD.COM.AU - A La Une - 04/Sep 20:45

Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval

Despite many obstacles, Dimerix is getting to the pointy end of things with its kidney drug trial program. ...

Articles similaires

Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval

stockhead.com.au - 04/Sep 20:45

Despite many obstacles, Dimerix is getting to the pointy end of things with its kidney drug trial program. ...

Dimerix first patient completes Phase 3 trial and enters into long-term DMX-200 Open Label Extension study

stockhead.com.au - 10/Sep 23:38

Dimerix has enrolled the first patient into the Open Label Extension study for its kidney disease drug candidate DMX-200 after ...

Key paediatric milestone reached in Dimerix’s kidney-disease drug trial

stockhead.com.au - 12/Sep 03:41

Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...

Key paediatric milestone reached in Dimerix’s kidney-disease drug trial

stockhead.com.au - 12/Sep 03:41

Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...

Bio Curious: Phone autism test strives to make diagnosis quicker and more blinkin’ simple

stockhead.com.au - 17/Sep 20:00

Blinklab expects rapid US approval for its phone-based autism test that can detect the condition within minutes. ...

A Personal Meditation On Growing Old In A Catastrophic Age – OpEd

eurasiareview.com - 15/Sep 23:33

By Rebecca Gordon Washington Postheadlinereads: “A big problem for young workers: 70- and 80-year-olds who won’t retire.” For the first time...

Indies Pharma looking to double sales after securing FDA drug approval

jamaica-gleaner.com - 11/Sep 05:05

Drug company Indies Pharma Jamaica Limited is looking to double next year’s revenues, following approval of its abbreviated new drug application,...

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

No end to road rage trial

dailynews.co.za - 17:07

Les derniers communiqués

Aucun élément